Nutriband (NASDAQ:NTRB – Get Free Report) and Ocular Therapeutix (NASDAQ:OCUL – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, dividends and institutional ownership.
Profitability
This table compares Nutriband and Ocular Therapeutix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nutriband | -430.35% | -109.07% | -95.54% |
| Ocular Therapeutix | -579.10% | -59.89% | -45.99% |
Earnings and Valuation
This table compares Nutriband and Ocular Therapeutix”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nutriband | $2.04 million | 48.46 | -$8.23 million | ($0.53) | -15.34 |
| Ocular Therapeutix | $51.95 million | 42.23 | -$265.94 million | ($1.42) | -7.04 |
Nutriband has higher earnings, but lower revenue than Ocular Therapeutix. Nutriband is trading at a lower price-to-earnings ratio than Ocular Therapeutix, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Nutriband has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500. Comparatively, Ocular Therapeutix has a beta of 0.97, indicating that its stock price is 3% less volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations and price targets for Nutriband and Ocular Therapeutix, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nutriband | 1 | 1 | 0 | 0 | 1.50 |
| Ocular Therapeutix | 1 | 1 | 11 | 0 | 2.77 |
Ocular Therapeutix has a consensus target price of $25.75, suggesting a potential upside of 157.76%. Given Ocular Therapeutix’s stronger consensus rating and higher possible upside, analysts plainly believe Ocular Therapeutix is more favorable than Nutriband.
Insider and Institutional Ownership
19.7% of Nutriband shares are held by institutional investors. Comparatively, 59.2% of Ocular Therapeutix shares are held by institutional investors. 52.2% of Nutriband shares are held by company insiders. Comparatively, 3.1% of Ocular Therapeutix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
Ocular Therapeutix beats Nutriband on 8 of the 14 factors compared between the two stocks.
About Nutriband
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd. for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
About Ocular Therapeutix
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company’s sustained-release hydrogel in combination with Regeneron’s large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Receive News & Ratings for Nutriband Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutriband and related companies with MarketBeat.com's FREE daily email newsletter.
